{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"The potential efficacy of ALT-803 in this patient population is measured by the responses based on bone marrow examination 1 and 3 months after the last dose of ALT-803.\n\nResponse was defined as follows: for AML and myelodysplastic syndromes (MDS) using the International Working Group modified criteria, non-Hodgkin lymphoma, and multiple myeloma using the International Myeloma Working Group Uniform Response Criteria, and acute lymphoblastic leukemia using protocol-specified criteria.","groups":[{"description":"Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.","id":"OG000","title":"ALT-803, IV, 1 mcg/kg"},{"description":"Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.","id":"OG001","title":"ALT-803, IV, 3 mcg/kg"},{"description":"Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.","id":"OG002","title":"ALT-803, IV, 6 mcg/kg"},{"description":"Weekly dose of ALT-803 at assigned dose once a week for 4 weeks.","id":"OG003","title":"ALT-803, IV, 10 mcg/kg"},{"description":"Weekly dose of ALT-803 at assigned dose subcutaneously, once a week for 4 weeks.","id":"OG004","title":"ALT-803, SQ, 6 mcg/kg"},{"description":"Weekly dose of ALT-803 at assigned dose , subcutaneously, once a week for 4 weeks.","id":"OG005","title":"ALT-803, SQ, 10 mcg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 months","title":"Number of Participants Experiencing Potential Efficacy of ALT 803","type":"PRIMARY","unitOfMeasure":"Participants"}